Shree Renuka Sugar posts dismal Q4 numbers

Vidrum / 15 Nov 2011

Shree Renuka Sugar posted a net loss of Rs 615 cr in Q2FY12 against net profits of 128 cr last quarter.
Shree Renuka Sugar has posted dismal Q4 numbers (the company has its year ending in September). It posted a net loss of Rs 615 cr as against net profits of 128 cr for the 4th quarter last year. This was mainly on the back of forex losses, which came in at Rs 569.8 cr. The stock is down 22% at Rs 40.20.

The company has business operations in India and Brazil. Due to a volatile global market, there was a depreciation of the Indian Rupee (by 9.5%) and Brazilian Real (by 18.8%) against the US Dollar, which resulted in huge forex losses of Rs 569.8 cr that affected the company’s bottomline.

Shree Renuka Sugar's net sales (consolidated) declined by 2.84% to Rs 2419 cr on a YoY basis. Higher sales in its Brazilian subsidiaries helped to off-set the lower sales in the Indian business. Its EBIDTA margins (consolidated) improved by 50 bps to 13.6%.

Indian Standalone Business

In Q4, the company's Indian standalone business showed a de-growth in revenues by 21% to Rs 1127 cr on a YoY basis, as revenue from the sugar segment declined by 43% to Rs 599 cr. The ethanol segment performed exceptionally well during the quarter, with its revenues increasing by a whopping 362% to Rs 108 cr. This comes mainly due to higher realisations, which increased by 18% on a YoY basis. The net result was seen in its improved EBITDA margins, which increased by 280 bps to 5.4%. 

Brazilian Operations

In its Brazilian business, the company has two subsidiaries, viz. 'Renuka do Brasil' and 'Renuka Vale do Ivai'. Its Q4 sales in Brazil increased by 17% to Rs 9098 cr on a YoY basis, while the EBIDTA margins declined by 500 bps to 23.70%. This is because  the performance of 'Renuka do Brasil' was impacted by a drought-like condition in its operational area, which resulted in a drop in cane yield (down 31%), leading to higher fixed costs during the quarter. However, 'Renuka Vale do Ivai' showed a good operational performance, with a rise in EBIDTA.

Overall, the company has posted weak Q4 numbers. It faced a setback in Sao Paulo, Brazil, where 'Renuka do Brasil' has its operations, and will take some time to recover from it. The Indian sugar business is also highly regulated by government, as the industry in North India is subject to high State Advisory Price (SAP), and the Maharashtra Co-operative Sugar Industry is facing a cash crunch due to lack of profits and net worth following losses accumulated over the last few seasons. 

We expect the sugar stocks to be in pressure for some time. Thus, we, at DSIJ, recommend that our readers avoid this counter. 

Key Financials (Consolidated)

Particulars Q4FY11 Q4FY10
Net Sales 2,419.00 2,489.90
Operational  EBIDTA 328.4 327.1
Interest 192.5 117.7
Depreciation 225.1 147.1
Foreign exchange gain /  loss -569.8 68.9
Net Profit / Loss -615.8 128.1

Segment-wise revenue and Profit (Standalone)

  Revenue PBIT
  Q4 FY11 Q4 FY10 % Change Q4 FY11 Q4FY10 % Change
Sugar  599.4 1056.4 -43.26 16.9 19.9 -15.08
Trading 416.6 339.7 22.64 6.5 8.9 -26.97
Co-generation 40.7 42.3 -3.78 -1.5 -1.9 21.05
Ethanol 108.7 23.5 362.55 18.6 -0.9 2166.67
Other 1 0.8 25 0.5 0.3 66.67
Less Inter Segment 39.1 23.4 67      
Total 1127.3 1439.3 -21.68 41 26.3 55.89

View our earlier update on sugar stocks being hit by steep hike in sugarcane prices

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.